Earnings Call · Q2 FY2023·2023-08-11

Q2 23EPS -11.76%·Rev n/aQ1 23EPS -94.12%·Rev n/aQ4 22EPS -10.00%·Rev n/aQ3 22EPS -100.00%*·Rev n/a⚠ consensus missing

Starling Oncology, Inc. TOI

Mark Hueppelsheuser — General Counsel

Dan Virnich — Chief Executive Officer

Mihir Shah — Chief Financial Officer

+9.0%1d on move date+9.0% vs SPY3d−3.6%5d−5.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TOI calls or request research access.

More TOI calls Browse calls Request research access